```
     FILE 'REGISTRY' ENTERED AT 10:47:58 ON 06 MAR 2009
                  EXP HEXAMIDINE/CN
L1             2 S E3
                  EXP VITAMIN B3/CN
L2             3 S E3

     FILE 'HCAPLUS' ENTERED AT 10:49:35 ON 06 MAR 2009
L3          1722 S L1
L4         31873 S L2
L5           114 S L3 AND L4
L6        330741 S SKIN OR TOPICAL OR DERMATOLOGICAL
L7            51 S L5 AND L6
L8            11 S L7 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

```
=> file registyry
'REGISTYRY' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 10:47:58 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 MAR 2009  HIGHEST RN 1115640-24-8
DICTIONARY FILE UPDATES:   4 MAR 2009  HIGHEST RN 1115640-24-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp hexamidine/cn
E1            1     HEXAMIDE, 2,6-DIAMINO-N-GLUCOPYRANOSYL-/CN
E2            1     HEXAMIDE, N,2-DIETHYL-3-OXO-/CN
E3            2 --> HEXAMIDINE/CN
E4            1     HEXAMIDINE (ANTIEPILEPTIC)/CN
E5            1     HEXAMIDINE (ANTISEPTIC)/CN
E6            1     HEXAMIDINE DIISETHIONATE/CN
E7            1     HEXAMIDINE ISETHIONATE/CN
E8            1     HEXAMINATE/CN
E9            2     HEXAMINE/CN
E10           1     HEXAMINE (HETEROCYCLE)/CN
E11           1     HEXAMINE (POTASSIUM REAGENT)/CN
E12           1     HEXAMINE CHROMATE/CN

=> s e3
L1            2 HEXAMIDINE/CN

=> d l1 1-2

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   3811-75-4  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Benzenecarboximidamide, 4,4'-[1,6-hexanediylbis(oxy)]bis-  (CA INDEX NAME)
```

OTHER CA INDEX NAMES:
CN Benzamidine, 4,4'-(hexamethylenedioxy)di- (7CI, 8CI)
OTHER NAMES:
CN 1,6-Bis(4-amidinophenoxy)hexane
CN 4,4'-(Hexamethylenedioxy)dibenzamidine
CN 4,4-Diamidino-1,6-diphenoxyhexane
CN Desmodine
CN Hexamidine
CN Hexamidine (antiseptic)
MF C20 H26 N4 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CSNB, DDFU, DRUGU, EMBASE, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

132 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
133 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 125-33-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- (CA INDEX NAME)
OTHER NAMES:
CN 2-Deoxyphenobarbital
CN 2-Desoxyphenobarbital
CN 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione
CN 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione
CN 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione
CN 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione
CN Hexamidine
CN Hexamidine (antiepileptic)
CN Hexamydin
CN Lepimidin
CN Liskantin
CN Milepsin
CN Misodine
CN Misolyne
CN Mizodin
CN Mizolin
CN Mylepsin
CN Mysedon
CN Mysoline
CN Neurosyn
CN NSC 41701
CN Primaclone

CN Primacone
CN Primakton
CN Primidon
CN Primidone
CN Pyrimidone Medi-pets
CN Resimatil
CN Roe 101
CN Sertan
DR 8023-71-0, 1340-05-2
MF C12 H14 N2 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1587 REFERENCES IN FILE CA (1907 TO DATE)
26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1590 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> exp vitamin b3/cn
E1            1     VITAMIN B2-ALDEHYDE-FORMING ENZYME (SCHIZOPHYLLUM COMMUNE ST
                    RAIN ATCC 38719 CLONE PBRAF)/CN
E2            1     VITAMIN B2-BUTYRATE/CN
E3            3 --> VITAMIN B3/CN
E4            1     VITAMIN B4/CN
E5            2     VITAMIN B5/CN
E6            1     VITAMIN B5 CALCIUM SALT/CN
E7            1     VITAMIN B6/CN
E8            1     VITAMIN B6 BIOSYNTHESIS PROTEIN (BACILLUS LICHENIFORMIS STRA
                    IN ATCC 14580 GENE PDX1)/CN
E9            1     VITAMIN B6 BIOSYNTHESIS PROTEIN (FRANKIA STRAIN CCI3)/CN
E10           1     VITAMIN B6 BIOSYNTHESIS PROTEIN (THERMOBIFIDA FUSCA STRAIN Y
                    X)/CN
E11           1     VITAMIN B6 BIOSYNTHESIS-ASSOCIATED SOR-LIKE PROTEIN (GINKGO
                    BILOBA)/CN
E12           1     VITAMIN B6 DIOCTANOATE/CN

=> s e3
L2            3 "VITAMIN B3"/CN

=> d l2 1-3 scan
```

'1-3' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinecarboxylic acid
MF C6 H5 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties
PPROP - Table of predicted properties
PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN β-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-
MF C9 H17 N O5
CI COM

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinecarboxamide
MF C6 H6 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 16.24 16.46

FILE 'HCAPLUS' ENTERED AT 10:49:35 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 5 Mar 2009 (20090305/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l1
L3        1722 L1

=> s l2
L4       31873 L2

=> s l3 and l4
L5         114 L3 AND L4

=> s skin or topical or dermatological
        296639 SKIN
         54653 TOPICAL
          3214 DERMATOLOGICAL
L6      330741 SKIN OR TOPICAL OR DERMATOLOGICAL

=> s l5 and l6
L7          51 L5 AND L6

=> s l7 and (PY<2003 or AY<2003 or PRY<2003)
      22983539 PY<2003
       4504786 AY<2003
       3973776 PRY<2003
L8          11 L7 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d l8 1-11 ti abs bib
```

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Novel dosage form comprising modified-release and immediate-release active ingredients
AB A dosage form comprising of a high dose, high solubility active ingredient as

modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

AN 2006:100738 HCAPLUS <<LOGINID::20090306>>

DN 144:198849

TI Novel dosage form comprising modified-release and immediate-release active ingredients

IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar

PA India

SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20060024365	A1	20060202	US 2005-134633	20050519	<--
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805	<--
	IN 193042	A1	20040626			
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805	<--
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122	
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122	
	US 20040096499	A1	20040520	US 2003-630446	20030729	<--
PRAI	IN 2002-MU697	A	20020805	<--		
	IN 2002-MU699	A	20020805	<--		
	IN 2003-MU80	A	20030122			
	IN 2003-MU82	A	20030122			
	US 2003-630446	A2	20030729			

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Skin care compositions comprising hexamidine, zinc oxide and niacinamide on a thin sanitary napkin

AB Disclosed is a sanitary napkin for wearing adjacent the pudendal region, having a skin care composition applied thereon, wherein the sanitary napkin has a caliper less than about 5.0 mm. The skin care composition can have about 0.001% to about 0.1% by weight of hexamidine, about 0.001% to about 10% by weight of zinc oxide, about 0.01% to about 10% by weight of niacinamide, and a carrier. Thus, a skin care composition contained hexamidine 0.1, panthenol 0.5, glycerin 0.1, niacinamide/chamomile (Phytoconcentrol Chamomile) 0.5, and a carrier 97.1%, the carrier comprising petrolatum 78.1, behenyl alc. 8.7, Beheneth-10 10.0, and fumed silica 3.2%, resp.

AN 2005:592136 HCAPLUS <<LOGINID::20090306>>

DN 143:120595

TI Skin care compositions comprising hexamidine, zinc oxide and niacinamide on a thin sanitary napkin

IN Warren, Raphael; Hammons, John Lee; Blevins, John Michael; Klofta, Thomas James; Minoguchi, Ryo; Pennington, Regina Leigh; Staudigel, James Anthony; Tanner, Paul Robert; Vatter, Michael Lee

PA USA

SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 152,924.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 24

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 20050148962 A1 20050707 US 2004-992430 20041118 <--
US 20030082219 A1 20030501 US 2002-152924 20020521 <--
AU 2005265258 A1 20060126 AU 2005-265258 20050621
CA 2570686 A1 20060126 CA 2005-2570686 20050621
WO 2006009996 A1 20060126 WO 2005-US21752 20050621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1778146 A1 20070502 EP 2005-766062 20050621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1968663 A 20070523 CN 2005-80020084 20050621
JP 2008503323 T 20080207 JP 2007-518174 20050621
BR 2005012331 A 20080304 BR 2005-12331 20050621
AU 2006209374 A1 20060928 AU 2006-209374 20060908
AU 2006209374 B2 20080214
AU 2006209374 B9 20080710
IN 2006DN07375 A 20070803 IN 2006-DN7375 20061206
MX 2006014523 A 20080710 MX 2006-14523 20061213
KR 2007032704 A 20070322 KR 2006-726863 20061220
AU 2007200811 A1 20070315 AU 2007-200811 20070223 <--
PRAI US 2001-968154 B2 20011001 <--
US 2002-152924 A2 20020521 <--
US 2004-581483P P 20040621
AU 2002-327797 A3 20021001 <--
AU 2003-301008 A3 20031216
WO 2005-US21752 W 20050621

L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions treatment of chronic inflammatory diseases
AB This invention defines novel compns. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents,

so as to produce an additive or synergistic physiol. effect of an anti-inflammatory nature.

AN 2005:369133 HCAPLUS <<LOGINID::20090306>>

DN 142:435774

TI Compositions treatment of chronic inflammatory diseases

IN Shapiro, Howard K.

PA USA

SO U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073, abandoned.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050090553	A1	20050428	US 2004-924945	20040824 <--
	US 20080234380	A1	20080925	US 2008-70518	20080220 <--
PRAI	US 1992-906909	B2	19920630 <--		
	US 1994-241603	B2	19940511 <--		
	US 1997-814291	B2	19970310 <--		
	US 2000-610073	B2	20000705 <--		
	US 2004-924945	A2	20040824		

OS MARPAT 142:435774

L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Compositions comprising an amidine and an alkane polyol

AB The present invention relates to cosmetic compns. containing 0.001 to 10% of an amidine, and 0.01 to 20% of an alkane polyol having a ClogP of from +0.2 to +1.55 and water. The present invention also relates to methods of using such cosmetic compns. to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying a safe and effective amount of such compns. to the skin of a mammal needing such treatment. For example, a moisturizing skin cream/lotion for hand and body skin care was prepared containing Tospearl 144A 1.00, sodium hydroxide 40% solution 0.022, dimethicone and dimithiconol (DC 1503) 1.00, benzyl alc. 0.25, D-panthenol 1.00, polyacrylamide (Sepigel 305) 1.50, fractionated coconut oil 0.40, DL-α-tocopherol acetate 0.25, petrolatum (white soft paraffin) 2.00, iso-Pr isostearate 1.50, behenyl alc. (Stenol 1822A) 0.42, cetyl alc. 95% 0.515, stearic acid 0.10, stearyl alc. (Crodacol S 95) 0.641, PEG-100-stearate (Myrj 59) 0.10, butylated hydroxytoluene 1.00, hexamidine diisethionate 0.10, Et paraben (Nipasol M) 0.07, isohexadecane (Arlamol HD) 3.00, Emulgade PL 68/50 0.20, glycerin 7.00, 1,2-hexanediol 3.00, disodium EDTA 0.10, and water, fragrance, and preservatives to 100%, resp.

AN 2004:1036844 HCAPLUS <<LOGINID::20090306>>

DN 142:11276

TI Compositions comprising an amidine and an alkane polyol

IN Elliott, Russell Phillip; McKay, Barnaby George Robert; Vanoosthuyze, Kristina Emma Inge

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103290	A2	20041202	WO 2004-US15049	20040514
	WO 2004103290	A3	20060817		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

```
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    EP 1477155          A1    20041117    EP 2003-253081         20030516 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    EP 1477157          A1    20041117    EP 2004-252687         20040507
    EP 1477157          B1    20080319
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
    US 20040228820      A1    20041118    US 2004-841193         20040507
    AT 389382           T     20080415    AT 2004-252687         20040507
    AU 2004240612       A1    20041202    AU 2004-240612         20040514
    CA 2524656          A1    20041202    CA 2004-2524656        20040514
    BR 2004010369       A     20060530    BR 2004-10369          20040514
    CN 1993102          A     20070704    CN 2004-80013265       20040514
    JP 2007526873       T     20070920    JP 2006-514357         20040514
    JP 4217740          B2    20090204
    MX 2005012322       A     20060130    MX 2005-12322          20051115
PRAI EP 2003-253081     A     20030516
    US 2001-338042P     P     20011113  <--
    WO 2004-US15049     W     20040514
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 5 OF 11  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Skin-protecting compositions to be delivered from absorbent
     articles
AB   The present invention relates to a novel composition for efficiently releasing
     hydrophilic or water-soluble skin care actives from an oleaginous
     composition  The substantially oleaginous composition of the present invention
     comprises: (1) at least one skin care active; (2) a release
     agent having an HLB of at least about 3; and (3) a hydrophobic barrier
     protectant.  The novel release composition may be topically applied to
     skin using a dispensing means such as an absorbent article, a
     wipe, a bandage, a pad, a canister, a stick, an aerosol dispenser, a
     sprayer, and the like.  For example, a release composition was formulated
     containing hexamidine diisethionate 0.1, Beheneth-10 6.3, Petrolatum 72.6,
     behenyl alc. 17.7, and fumed silica 3.3 %, then deposited on a top sheet
     of an absorbent article.
AN   2004:282815  HCAPLUS <<LOGINID::20090306>>
DN   140:309487
TI   Skin-protecting compositions to be delivered from absorbent
     articles
IN   Osborne, Scott Edward; Deckner, George Endel; Klofta, Thomas James; Vega,
     Victor Nicholas
PA   The Procter & Gamble Company, USA
SO   U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 41,266, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 4
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
```

```
PI   US 6716441          B1    20040406    US 1999-466343         19991217 <--
     ZA 9902000          A     19990913    ZA 1999-2000           19990311 <--
     TR 200002601        T2    20001221    TR 2000-2601           19990311 <--
     AT 392906           T     20080515    AT 1999-912417         19990311 <--
     CA 2393732          A1    20010621    CA 2000-2393732        20001213 <--
     CA 2393732          C     20051220
     WO 2001043717       A1    20010621    WO 2000-US33741        20001213 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1237535          A1    20020911    EP 2000-984288         20001213 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003516955       T     20030520    JP 2001-544656         20001213 <--
     MX 2002005516       A     20020902    MX 2002-5516           20020531 <--
     US 20040175343      A1    20040909    US 2004-804381         20040319 <--
PRAI US 1998-41266       B2    19980312  <--
     US 1999-466343      A     19991217  <--
     WO 2000-US33741     W     20001213  <--
RE.CNT  69    THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 6 OF 11  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Cosmetic use of a polymer comprising LCST units
AB   The invention concerns the cosmetic use, in a composition comprising a physiol.
     acceptable medium, as an agent for matifying the skin and/or for
     concealing blemishes and/or for camouflaging pores, of at least one
     hydrosol. or hydrodispersible polymer comprising hydrosol. or
     hydrodispersible units and LCST units, the said LCST units having, in
     water, a demixing temperature (or cloud point) of 5°C to 40°C at a
     concentration by weight of 1%, the said composition being free of any other
compound having
     an optical effect selected from fillers, ,nacres, pigments, matifying
     polymers and tightening agents.  The invention also concerns the use, in
     the cosmetic treatment for greasy or combination skin, of a
     composition containing the said polymer in a physiol. acceptable medium,
excluding
     any other compound having an optical effect.  A matifying cream was prepared
     containing an aqueous phase comprising Na polyacrylate carrying grafts of
     Jeffamine M-2005, glycerin, preservatives, EDTA, and demineralized water
     and an oily phase containing stearyl alc., Cosmacol PSE, Arlacel 165,
     cyclohexadimethylsiloxane, and preservative.
AN   2004:60274  HCAPLUS <<LOGINID::20090306>>
DN   140:116974
TI   Cosmetic use of a polymer comprising LCST units
IN   Chevalier, Veronique; Lalloret, Florence
PA   L'Oreal, Fr.
SO   PCT Int. Appl., 54 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2004006872        A1    20040122    WO 2003-EP8484         20030715 <--
```

```
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     FR 2842415           A1    20040123    FR 2002-8974          20020716 <--
     FR 2842415           B1    20050429
     AU 2003250199        A1    20040202    AU 2003-250199        20030715 <--
PRAI FR 2002-8974         A     20020716  <--
     US 2002-399445P      P     20020731  <--
     WO 2003-EP8484       W     20030715
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 7 OF 11  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Disposable absorbent article having a skin care composition
     containing an enzyme inhibitor
AB   An absorbent article, at least a portion of which comprises a skin
     care composition that comprises an enzyme inhibitor and is at least partially
     transferred from the article to the skin of a wearer of the
     article as a result of normal contact, wearer motion and/or body heat.
     The enzyme inhibitor is transferred to the skin with the
     skin care composition and is available at the skin/urine and
     skin/feces interfaces to inhibit enzymic activity on the
     skin and to reduce or prevent the occurrence of inflammation.
     Repeated application of similar treated articles to the wearer's
     skin provides an available source with which the enzyme inhibitor
     transfers onto the skin continuously over time and accumulates
     to provide a proactive defense against harmful enzymes for the treatment
     and/or prevention of diaper dermatitis.  A skin care composition was
     obtained by mixing the following components: 99 parts a melted base composition
     containing 58 parts petrolatum, 41 parts stearyl alc., and 1 part Aloe extract
     with 1 part tranexamic acid.
AN   2003:570679  HCAPLUS <<LOGINID::20090306>>
DN   139:122826
TI   Disposable absorbent article having a skin care composition
     containing an enzyme inhibitor
IN   Roe, Donald Carroll; Rourke, Francis James; Osborne, Scott Edward
PA   The Procter & Gamble Company, USA
SO   U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 623,813.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 4
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   US 20030139711        A1    20030724    US 2002-323386          20021218 <--
     US 6703536           B2    20040309
     WO 9945973           A1    19990916    WO 1999-US5311          19990311 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
             MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
             TR, TT, UA, UG, US, UZ, VN, YU, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
```

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-41266 B2 19980312 <--
WO 1999-US5311 A 19990311 <--
US 2000-623813 B2 20000908 <--

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Skin care compositions comprising low concentrations of skin treatment agents

AB Skin care compns. that are suitable for application on absorbent articles such as panty liners and interlabial products for delivery of the skin care compns. effective in preventing and/or reducing skin disorders related to erythema, malodor, and skin bacterial infections onto an external or internal area of the skin are described. The composition comprises (a) about 0.001-0.1% by weight of hexamidine; (b) about 0.001-10% by weight of zinc oxide; (c) about 0.01-10% by weight of niacinamide; and (d) a carrier. For example, a skin care composition carrier system contained petrolatum 78.1%, behenyl alc. 8.7%, Beheneth-10 10.0%, and fumed silica 3.2%. A skin care composition was prepared from 97.1% of the carrier system, mixed with 0.7% ZnO Premix, 0.1% hexamidine, 0.5% panthenol, 0.1% glycerin, 1.0% niacinamide, and 0.5% chamomile extract

AN 2003:334402 HCAPLUS <<LOGINID::20090306>>

DN 138:343474

TI Skin care compositions comprising low concentrations of skin treatment agents

IN Warren, Raphael; Blevins, John Michael; Klofta, Thomas James; Minoguchi, Ryo; Pennington, Regina Leigh; Staudigel, James Anthony; Tanner, Paul Robert; Vatter, Michael Lee

PA The Procter & Gamble Company, USA

SO U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 968,154.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 24

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030082219	A1	20030501	US 2002-152924	20020521 <--
CA 2462457	A1	20030410	CA 2002-2462457	20021001 <--
WO 2003028776	A1	20030410	WO 2002-US31135	20021001 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002327797	A1	20030414	AU 2002-327797	20021001 <--
EP 1432457	A1	20040630	EP 2002-763808	20021001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013062	A	20040928	BR 2002-13062	20021001 <--
HU 2004001764	A2	20041129	HU 2004-1764	20021001 <--
CN 1561233	A	20050105	CN 2002-819197	20021001 <--
JP 2005504591	T	20050217	JP 2003-532104	20021001 <--
TW 233364	B	20050601	TW 2002-91123298	20021009 <--
US 20030206943	A1	20031106	US 2003-444241	20030523 <--
US 20040170589	A1	20040902	US 2004-789967	20040227 <--
ZA 2004001881	A	20050420	ZA 2004-1881	20040308 <--

	MX 2004003014	A	20040715	MX 2004-3014	20040330 <--
	US 20050129651	A1	20050616	US 2004-992383	20041118 <--
	US 20050148962	A1	20050707	US 2004-992430	20041118 <--
	US 20050154362	A1	20050714	US 2005-59763	20050217 <--
	US 20060062816	A1	20060323	US 2005-222654	20050909 <--
	AU 2006209374	A1	20060928	AU 2006-209374	20060908
	AU 2006209374	B2	20080214		
	AU 2006209374	B9	20080710		
	AU 2007200811	A1	20070315	AU 2007-200811	20070223 <--
	US 20070286876	A1	20071213	US 2007-894165	20070820 <--
PRAI	US 2001-968154	A2	20011001 <--		
	US 2002-152924	A	20020521 <--		
	AU 2002-327797	A3	20021001 <--		
	WO 2002-US31135	W	20021001 <--		
	US 2003-444241	A2	20030523		
	AU 2003-301008	A3	20031216		
	US 2004-789967	A2	20040227		
	US 2004-581483P	P	20040621		

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Cosmetic use of a vinylpyrrolidone-alkene copolymer to modify the appearance of the skin
AB A cosmetic composition for modifying the appearance of the skin contains a copolymer of vinylpyrrolidone with a C10-40 alkene. The composition softens the skin and/or the lips, and/or wipes out rings under the eyes, and hides the skin wrinkles. Thus, an oil-in-water emulsion contained in the oily phase stearyl alc. 1, Cosmacol PSE 1.5, cyclohexadimethyl siloxane 10, Triacontanyl PVP (Unimer U-6) 3, in the aqueous phase glycerin 5, Hostacerin AMPS 0.4, Dry-Flo 3, xanthan gum 0.2, NaOH 0.01, preservative 0.7, and water to 100%.
AN 2002:634279 HCAPLUS <<LOGINID::20090306>>
DN 137:174546
TI Cosmetic use of a vinylpyrrolidone-alkene copolymer to modify the appearance of the skin
IN Lordi, Kali; Ulrich, Maria; Chevalier, Veronique; Quest, Melanie; Potin, Anthony
PA L'Oreal, Fr.
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1232742	A1	20020821	EP 2002-290335	20020212 <--
	EP 1232742	B1	20070808		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20020164294	A1	20021107	US 2001-784210	20010216 <--
	FR 2820972	A1	20020823	FR 2001-2423	20010222 <--
	FR 2820972	B1	20030516		
	AT 369116	T	20070815	AT 2002-290335	20020212 <--
	ES 2290255	T3	20080216	ES 2002-290335	20020212 <--
	JP 2002249414	A	20020906	JP 2002-37425	20020214 <--
	US 20020182158	A1	20021205	US 2002-80066	20020222 <--
	JP 2007145873	A	20070614	JP 2007-67189	20070315 <--
PRAI	US 2001-784210	A	20010216 <--		
	FR 2001-2423	A	20010222 <--		
	JP 2002-37425	A3	20020214 <--		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Biochemical germanium complexes with high therapeutic efficiency and wide application spectrum
AB A substance for therapeutic, prophylactic, alimentary and cosmetic uses comprises a complex of a medicament or biol. active compound with an organogermanium compound (OGC), with the general formula of Lk(OGC)m(solv)n (L = medicament, solv = water or organic solvent, k, m = ≥1, n ≥ 0). The complex can be applied for expansion of therapeutic effects spectrum, strengthening of therapeutic effect and decrease of medicament toxicity. An organogermanium compound corresponds to, e.g., 1-germa-2,8,9-trioxa-5-azatricyclo[3.3.3.01,5]undecane or 1-germa-2,8-dioxa-5-azabicyclo[3.3.01,5]octane in the doses of 0.001-0.1 g per day. The method allows considerable increase of complex pharmacol. activity of medicaments for a wide diversity of diseases and decrease of the medicaments toxicity. For example, complexes of OGC with tranquilizers (diazepam, mezapam, phenazepam, etc.) were more efficient compared to initial tranquilizers concerning decrease of insomnia, suppression of phobia, anxiety, agitation and tensity, and also showed anti-inflammatory, antihypoxic, immunostimulating, reparing, and nootropic effects.
AN 2000:144730 HCAPLUS <<LOGINID::20090306>>
DN 132:189687
TI Biochemical germanium complexes with high therapeutic efficiency and wide application spectrum
IN Soloviev, Evgeny Vladimirovich; Shcherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich; Kotrelev, Mikhail Vladimirovich; Pavlov, Konstantin Vitalevich; Khromova, Nataliya Yurievna; Komalenkova, Nina Georgievna
PA Fr.
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010561	A1	20000302	WO 1998-EP5214	19980817 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9893432	A	20000314	AU 1998-93432	19980817 <--
	EP 1105117	A1	20010613	EP 1998-946360	19980817 <--
	R: CH, DE, FR, GB, LI				
	RU 2233286	C2	20040727	RU 2001-107254	19980817 <--
	US 6451850	B1	20020917	US 2001-763222	20010514 <--
PRAI	WO 1998-EP5214	A	19980817 <--		

OS MARPAT 132:189687
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Disposable absorbent article having a skin care composition containing an enzyme inhibitor
AB An absorbent article, at least a portion of which comprises a skin care composition that comprises an enzyme inhibitor and is at least partially

transferred from the article to the skin of a wearer of the article as a result of normal contact, wearer motion and/or body heat is provided. The enzyme inhibitor is transferred to the skin with the skin care composition and is available at the skin /urine and skin/feces interfaces to inhibit enzymic activity on the skin and to reduce or prevent the occurrence of inflammation. Repeated application of similar treated articles to the wearer's skin provides an available source with which the enzyme inhibitor transfers onto the skin continuously over time and accumulates to provide a proactive defense against harmful enzymes for the treatment and/or prevention of diaper dermatitis. An absorbent article having a topsheet comprising a skin care composition and an enzyme inhibitor was prepared The composition contained acetohydroxamic acid 1, SEFA cottonate 85, and SEFA behenate 15 parts.

AN 1999:595013 HCAPLUS <<LOGINID::20090306>>

DN 131:219213

TI Disposable absorbent article having a skin care composition containing an enzyme inhibitor

IN Roe, Donald Carroll; Rourke, Francis James; Osborne, Scott Edward

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9945973	A1	19990916	WO 1999-US5311	19990311 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9902000	A	19990913	ZA 1999-2000	19990311 <--
	CA 2322503	A1	19990916	CA 1999-2322503	19990311 <--
	AU 9930795	A	19990927	AU 1999-30795	19990311 <--
	BR 9908565	A	20001212	BR 1999-8565	19990311 <--
	TR 200002601	T2	20001221	TR 2000-2601	19990311 <--
	EP 1061962	A1	20001227	EP 1999-912417	19990311 <--
	EP 1061962	B1	20080423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY				
	HU 2001001070	A2	20010730	HU 2001-1070	19990311 <--
	JP 2002505916	T	20020226	JP 2000-535385	19990311 <--
	AT 392906	T	20080515	AT 1999-912417	19990311 <--
	MX 2000008934	A	20010328	MX 2000-8934	20000912 <--
	US 20030139711	A1	20030724	US 2002-323386	20021218 <--
	US 6703536	B2	20040309		
PRAI	US 1998-41266	A	19980312 <--		
	WO 1999-US5311	W	19990311 <--		
	US 2000-623813	B2	20000908 <--		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT